Compare IDEXX Laboratories, Inc. (IDXX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nvidia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Nvidia Corp trades at $205.28 (market cap $4.92T). The key difference: Nvidia Corp is far larger — about 110.6× IDEXX Laboratories, Inc.'s market cap, and Nvidia Corp pays a 0.49% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NVDA | |
|---|---|---|
Market Cap | $44.48B | $4.92T |
Sector | Health | Technology |
52-Week High | $766.68 | $235.75 |
52-Week Low | $520.87 | $165.17 |
Enterprise Value | $45.38B | $4.86T |
Dividend Yield | — | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
NVIDIA (NVDA) trades at $205.95, up 1.55% on the day, with a neutral technical signal. The stock exhibits exceptional fundamental strength, with revenue surging to $130.50B in 2025 and net income margin reaching 62.97%. Recent quarterly earnings have consistently exceeded expectations, and analyst consensus remains strongly bullish with a $325.86 price target, though some institutional investors have recently trimmed positions.
The outlook is supported by dominant positioning in AI infrastructure, with revenue growth expected to continue. Key risks include peak AI spending concerns, intensifying competition, and high valuation multiples. The stock's performance is closely tied to the sustainability of the AI investment cycle and its ability to maintain technological leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
